BPC-157: Why the Internet Is Calling It the 'Wolverine Peptide'
BPC-157 picked up a Marvel-superhero nickname, a podcast spotlight, and an FDA panel review — but the human evidence is still almost nonexistent.
BPC-157 safety is not settled. Learn what human studies, cancer concerns, and product-quality risks mean before first use.

BPC-157 picked up a Marvel-superhero nickname, a podcast spotlight, and an FDA panel review — but the human evidence is still almost nonexistent.
The FDA is reconsidering BPC-157 for ulcerative colitis. Here's the gut-specific evidence map — IBD, leaky gut, IBS, ulcers — and what functional clinics actually prescribe.
Tirzepatide and semaglutide produce nearly identical weight loss across reproductive stages. Pairing GLP-1 peptides with HRT increases loss by ~30%.
Avocados, eggs, olive oil, oats, and Greek yogurt are the five foods with peer-reviewed evidence for naturally boosting GLP-1, Ozempic's hormone.
Tirzepatide drives an average 22.5% body-weight loss in trials — but stopping the drug leads to roughly 14% regain in a year, even with diet and exercise.
Most patients on Ozempic, Wegovy, or Zepbound hear about nausea and stop there. The full safety profile includes lean muscle loss, sulfur burps, gallstones, NAION vision risk, anesthesia warnings, and more. A research-grounded guide to what gets left out of the 15-minute appointment.
How the three big GLP-1 drugs really compare on weight loss, cardiovascular benefit, dosing schedule, side effects, and cost.
SURMOUNT-5 settled the indirect-comparison era. Here is what the head-to-head trial actually showed about tirzepatide versus semaglutide for fat loss.
From semaglutide to retatrutide and tesamorelin: the seven peptides reshaping obesity care, what trials really show, and what to ask before starting.

Tesamorelin is trending as a midlife belly-fat peptide, but the FDA approval, the 18% visceral-fat number, and the cancer warnings tell a more complicated story for women over 40.
BPC-157 safety is not settled.
Learn what human studies, cancer concerns, and product-quality risks mean before first use.
The goal isn’t to be comfortable with change — it’s to be comfortable with one small change, on a schedule, held for a year.
We’re recording with NotebookLM. Expect a deep-dive and a short-form version of each issue’s best essays, delivered to your favorite podcast app when we launch.